We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$349M
AUM Growth
+$53.4M
Cap. Flow
+$36.4M
Cap. Flow %
10.41%
Top 10 Hldgs %
7.12%
Holding
478
New
39
Increased
273
Reduced
76
Closed
38

Top Buys

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$2.36M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$1.99M
3
LRCX icon
Lam Research
LRCX
+$1.97M
4
IDXX icon
Idexx Laboratories
IDXX
+$1.96M
5
TKO icon
TKO Group
TKO
+$1.96M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.85M
2
KKR icon
KKR & Co
KKR
+$1.62M
3
UAL icon
United Airlines
UAL
+$1.62M
4
CBRE icon
CBRE Group
CBRE
+$1.61M
5
NU icon
Nu Holdings
NU
+$1.58M

Sector Composition

Rank Sector Weight
1 Financials 33.25%
2 Healthcare 17.27%
3 Technology 14.61%
4 Industrials 8.9%
5 Consumer Discretionary 5.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHRS icon
401
GH Research
GHRS
$2.03B
$127K 0.04%
8,869
+1,540
+21% +$21.5K
NUVL
402
DELISTED
Nuvalent
NUVL
$126K 0.04%
1,461
+254
+21% +$20.1K
VIR icon
403
Vir Biotechnology
VIR
$1.5B
$124K 0.04%
21,798
+3,784
+21% +$19.3K
RCKT icon
404
Rocket Pharmaceuticals
RCKT
$397M
$121K 0.03%
37,064
+6,434
+21% +$20.3K
EWTX icon
405
Edgewise Therapeutics
EWTX
$4.84B
$120K 0.03%
7,380
+1,282
+21% +$18.2K
PCVX icon
406
Vaxcyte
PCVX
$8.67B
$119K 0.03%
3,302
+573
+21% +$19K
ELVN icon
407
Enliven Therapeutics
ELVN
$4.35B
$118K 0.03%
5,787
+1,004
+21% +$20.2K
SMMT icon
408
Summit Therapeutics
SMMT
$11.9B
$117K 0.03%
5,644
+980
+21% +$23.8K
WVE icon
409
Wave Life Sciences
WVE
$1.2B
$116K 0.03%
15,804
+2,744
+21% +$22.2K
IMVT icon
410
Immunovant
IMVT
$8.24B
$115K 0.03%
7,138
+1,239
+21% +$20.1K
RNAC icon
411
Cartesian Therapeutics
RNAC
$265M
$114K 0.03%
11,112
+1,929
+21% +$21.7K
DNLI icon
412
Denali Therapeutics
DNLI
$4B
$111K 0.03%
7,624
+1,324
+21% +$19K
BHVN icon
413
Biohaven
BHVN
$2.19B
$110K 0.03%
7,299
+1,267
+21% +$18.4K
CVAC
414
DELISTED
CureVac
CVAC
$110K 0.03%
20,319
+3,527
+21% +$19.1K
JANX icon
415
Janux Therapeutics
JANX
$1B
$109K 0.03%
4,452
+773
+21% +$18.8K
APGE icon
416
Apogee Therapeutics
APGE
$10.2B
$108K 0.03%
2,718
+472
+21% +$18K
SYRE icon
417
Spyre Therapeutics
SYRE
$9.29B
$108K 0.03%
6,425
+1,115
+21% +$18.2K
RGNX icon
418
Regenxbio
RGNX
$688M
$108K 0.03%
11,155
+1,936
+21% +$17.1K
RXRX icon
419
Recursion Pharmaceuticals
RXRX
$1.76B
$107K 0.03%
22,009
+3,821
+21% +$20.1K
KALV
420
DELISTED
KalVista Pharmaceuticals
KALV
$106K 0.03%
8,693
+1,509
+21% +$20.9K
SLN
421
Silence Therapeutics
SLN
$729M
$106K 0.03%
20,374
+3,537
+21% +$19.6K
VKTX icon
422
Viking Therapeutics
VKTX
$4.02B
$105K 0.03%
3,982
+692
+21% +$20.6K
BCYC
423
Bicycle Therapeutics
BCYC
$288M
$101K 0.03%
13,094
+2,273
+21% +$17.2K
AKRO
424
DELISTED
Akero Therapeutics
AKRO
$101K 0.03%
2,125
+369
+21% +$17.9K
ALLO icon
425
Allogene Therapeutics
ALLO
$725M
$101K 0.03%
81,276
+14,110
+21% +$16.8K
15 16
17
18 19

Similar funds

WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
RGC
Roberts, Glore & Co Deerfield, Illinois $364M AUM 19.54% 1-Year Est. Return

Virtus Investment Advisers's Q3 2025 Portfolio in Review

As of Q3 2025, Virtus Investment Advisers held 478 positions worth $349M, up 18% from $296M the previous quarter. Its ten largest holdings account for 7.1% of the portfolio.

Virtus Investment Advisers deployed $36.4M of net new capital in Q3 2025, opening 39 new positions and adding to 273 existing holdings. Its largest new stake was Oxford Lane Capital: 129,209 shares worth $2.19M.

By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 33% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Incyte, an estimated $1.85M trimmed.

  • Virtus Investment Advisers's largest Q3 2025 buy was Oxford Lane Capital: 129,209 shares worth $2.19M.
  • Virtus Investment Advisers added most to Prospect Capital in Q3 2025, an estimated $697K increase.
  • Virtus Investment Advisers's biggest Q3 2025 reduction was Incyte, cutting an estimated $1.85M.
  • Virtus Investment Advisers fully exited KKR & Co in Q3 2025, selling an estimated $1.62M.
  • Virtus Investment Advisers's ten largest holdings make up 7.1% of its $349M portfolio in Q3 2025.
  • Virtus Investment Advisers opened 39 new positions and closed 38 in Q3 2025.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $349M.

Based on Virtus Investment Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.